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ABSTRACT 
Objective: The aim of the current study was to isolate and identify the bacteriocinogenic strain exhibiting broad range antimicrobial activity and 
antibiofilm activity from the soil of animal farms. 
Methods: In the current study, bacterial strains were isolated from soil of twelve different regions of the animal farm all over India and screened for 
antimicrobial activity against Staphylococcus epidermidis, Micrococcus luteus, Pseudomonas fluorescence and Escherichia coli. Antibiofilm ability of 
these selected strains was checked on preformed biofilm of S. epidermidis and in addition biofilm disruption potential was also determined. The 
potent bacterial strain was identified at the molecular level by 16S ribosomal DNA (rDNA) sequencing. 
Results: 30 out of 231 strains isolated from soil were selected on the basis of antibacterial activity against S. epidermidis. One potential candidate 
(GAS 101) exhibited ≥99% inhibition against S. epidermidis, M. luteus, P. fluorescence and E. coli and also showed antibiofilm activity. GAS 101 16S 
rDNA sequencing data identified it as Bacillus subtilis. The sequence of B. subtilis was submitted to genbank under accession no. KJ564301. 
Conclusion: B. subtilis GAS 101 isolated from soil of animal farm showed the antibacterial activity against all indicator organisms and also displayed 
antibiofilm activity against preformed biofilm and inhibited biofilm formation of S. epidermidis. 
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Bacterial nosocomial infections can pose a major risk mainly in 
immune-compromised patients. Advancement in medical sciences 
has led to the increased use of invasive devices resulting in high 
rates of infection [1]. Bacteriocins are ribosomally synthesized 
peptides which bacteria use as their natural defense mechanism in 
the same niche area. Bacteriocins have many properties like low 
toxicity, potency, narrow and broad spectrum effectiveness and in 
situ production. These properties indicate that bacteriocin can be 
used as alternate to antibiotic [2]. Production of bacteriocin is 
widespread in nature; a single bacterial species has been reported to 
produce 10 to 100 different types of bacteriocins [3]. Lactic acid 
bacteria (LAB) and Bacillus species both have gained the focus 
because of the ability to produce broad-spectrum inhibitory activity 
and GRAS status by the US FDA. Nisin and pediocin are the most 
studied antimicrobial substance from LAB which are commonly used 
in food production industry as a preservative agent and in the 
pharmaceutical industry as a health care product [4, 5].  
An antimicrobial substance produced by Bacillus species may be 
placed on the second place after LAB because of the diversity in the 
antimicrobial peptide (AMP) due to different chemical structures [6]. 
The Bacillus subgroup has been reported to produce a large number of 
AMPs and this can be a good source to explore the novel antimicrobial 
substances [7, 8]. Subtilin synthesized by B. subtilis is a cationic AMP 
which belongs to lantibiotic and has been studied extensively. It has 
been shown to be active against broad spectrum gram positive 
bacteria and acts via pore formation [9]. A number of reported 
bacteriocins is very less as compared to the reported bacterial species, 
so necessitating a need to explore the properties and therapeutic 
applications of bacteriocins. The objective of the current study was to 
isolate the bacteria producing antimicrobial substance from soil of 
animal farm. The soil is a rich source of microorganisms, as it provides 
an enhanced environment for the growth of microbes, which 
contributes towards enormous diversity of bacteria. In the current 
study, we have isolated different microbes which are able to produce 
antimicrobial substances from the soil of animal farm using de 
Man, Rogosa and Sharpe (MRS) agar plates. The isolate that possessed 
the broad activity against indicator organisms and was able to disrupt 
biofilm was further identified by molecular characterization.  
MATERIALS AND METHODS 
Chemicals  
The Chemicals and media used in the current study were procured 
from Hi-Media, CDH and Sigma-Aldrich. 
Methods 
Bacterial strains and growth conditions 
Four different microorganisms S. epidermidis (MTCC no. 435), P. 
fluorescence (MTCC No. 2421), M. luteus (MTCC No. 106) and E. coli 
(MTCC No. 443) used in the current study were procured from 
MTCC, Chandigarh. All bacteria were cultured in nutrient broth at 37 
°C for 16-18 h.  
Isolation of antimicrobial substance producing bacteria from 
soil of animal farm 
Bacterial strains were isolated from soil collected near the dairy of 
the various region of India (table 1). One gram of soil was mixed 
with 9 ml of autoclaved distilled water, homogenized using a vortex 
mixture and serially diluted with autoclaved water. Subsequently, 
100 μl of each dilution was spread onto MRS agar plate (Hi-media) 
and the plates were incubated at 30 °C for 24 h. Well-isolated 
colonies were inoculated into fresh MRS broth for stock preparation.  
Inhibition spectrum of cell free supernatant (CFS) of isolated 
bacterial strains 
The inhibition spectrum of each isolate was examined using the 96 
well microtiter plate assay against indicator organisms. The 
supernatant was obtained by centrifugation (10,000 ×g, 15 min at 4 
°C) of culture grown in MRS broth at 30 °C for 24 h. CFS from overnight 
grown culture was incubated with the 1x106 cfu/ml of the indicator 
organisms in each well of the 96 well plates [10]. Three wells in each 
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plate served as sterility control (without inoculum). Plates were 
incubated at 37 °C for 16-18 h and then examined for the growth 
inhibition with respect to control (indicator organism without CFS). 
The assay was carried out in triplicates and repeated thrice.  
Determination of activity unit per ml (AU/ml)  
Antimicrobial activity (AU/ml) was expressed as the reciprocal of 
the highest dilution that gave a definite zone of inhibition multiplied 
by a dilution factor [11]. 1x106 cfu/ml of S. epidermidis was treated 
with the 1:2-1:128 dilution of the CFS from each isolate and 
incubated at 37 °C for 16-18 h. The highest dilution showing 
inhibition activity was considered as antimicrobial activity unit. 
Antibiofilm activity of cell-free supernatant 
CFS from each isolate was tested for its potential antibiofilm activity 
against preformed S. epidermidis biofilm and also on its biofilm 
formation. 
Inhibition of cell attachment  
CFS from each isolate was incubated with 1x106 
The plates containing 1x10
cfu/ml of S. 
epidermidis in the 96 well plate and incubated at 37 °C for 48 h to 
allow cell attachment and biofilm development. The plate was 
washed with phosphate buffer saline (PBS) and the crystal violet 
staining assay was performed [12]. Evaluation of % reduction in 
biofilm was evaluated by- 
% inhibition = [1 − (
absorbance of treated bacteria
absorbance of untreated bacteria
)] X 100 
Reduction of biofilm growth and development 
6 
Molecular characterization and phylogenetic analysis of 16 S 
rDNA sequence of potential strain  
cfu/ml of S. epidermidis were incubated 
at 37 °C for 48 h to allow cell attachment and biofilm development. 
The wells were properly washed after incubation with PBS to 
remove unbound cells. CFS from each isolate was added to the well 
and further incubated for 24h. The plate was washed with PBS and 
crystal violet assay was performed as discussed above.  
Genomic DNA of the selected strain was isolated by 
cetyltrimethylammonium bromide (CTAB) method according to 
Cullings et al. 1992 [13]. The 16S rDNA of the strain (GAS 101) was 
amplified using universal primers 8-27F AGAGTTTGATCCTGGCTCAG 
and 1492R GGTTACCTTGTTACGACTTC; the sequence was submitted 
to Genbank (accession no. KJ564301). The phylogenetic tree of the 
amplified sequence of 16S rDNA of B. subtilis strains GAS101 with 
closely related Bacillus species was constructed by CLUSTAL W 
software. 
RESULTS 
Isolation of bacterial strains possessing antimicrobial activity 
The isolation of bacterial strains from soil of animal farm possessing 
antimicrobial activity against gram positive and gram negative 
indicator bacteria was undertaken. Soil provides a natural habitat to 
bacteria and research shows that it is the well-reported resource for 
diverse microbiota [14]. Soil samples were collected in sterile 
conditions from twelve different regions of India (table 1). The 
colonies (231) obtained on the MRS agar plate were streaked again 
and transferred into MRS broth for isolating pure culture. These 
bacteria were initially screened for inhibition activity against S. 
epidermidis by checkerboard dilution method and 30 strains were 
selected for further study. 
  
Table 1: Soil samples collected from different regions of India 
Sample no. Collection site Total isolates Isolates with antimicrobial activity 
1 Ghaziabad (U. P.) 26  1  
2 Ghazipur (Delhi) 33  10 
3 Gurgaon (Haryana) 12  2 
4 Bijnor (U. P.) 19  4 
5 Agra (U. P.) 17  3 
6 Mathura (U. P.) 35  9 
7 Bulandsahar (U. P.) 17  1  
8 Faridabad (Haryana) 22  0  
9 Dehradun (Uttaranchal) 24  0  
10 Sirdi (Maharastra) 14 0 
11 Bhopal (M. P.) 17 0 
12 Sikar (Rajasthan)  12 0 
Total  231 30 
  
Antimicrobial spectrum of cell free supernatant of selected 
strains 
Antimicrobial activity of screened bacterial CFS was examined further 
against P. fluorescence, M. luteus and E. coli indicator organisms by 96 
well microtiter plate assay to select the isolate possessing the broad 
range antimicrobial activity. The results of checker board assay 
indicates that 28 out of 30 strains showed >90% inhibition against E. 
coli, whereas 20 out of 30 showed inhibition of P. fluorescence cells and 
19 strains were active against M. luteus (table 2). In totality 10 strains 
showed >90% inhibition against all chosen bacteria. 
Determination of AU/ml 
The AU/ml of CFS from all selected bacterial strains was checked 
against S. epidermidis as indicator organism (table 2). The activity 
ranged from 80 to 800 AU/ml and the highest activity was observed 
for GAS 101 strain up to 800AU/ml against S. epidermidis. 
Antibiofilm activity of cell free supernatant 
The antibiofilm activity of all the selected strains (30) after initial 
screening was checked against S. epidermidis biofilm. The capability 
of S. epidermidis to produce biofilm was checked on the congo red 
agar (data not shown). S. epidermidis is an opportunistic dermal 
pathogen which can cause infections on indwelling medical devices 
and surgical wounds by forming biofilm [15]. The capability of S. 
epidermidis to form biofilm complicates its removal as it is more 
resilient to eradication [16]. In the current study, the curing i.e. 
biofilm disruption as well as the preventive prospective, especially 
inhibition of biofilm formation, was investigated. Ten out of 30 
chosen stains were potentially able to inhibit >90% S. epidermidis 
biofilm formation upon CFS incubation (table 2) and 4 strains could 
demolish the preformed biofilm by S. epidermidis. 
Molecular characterization of potential candidate 
The isolate which displayed antimicrobial activity against all selected 
strains, antibiofilm activity (formation and disruption) against S. 
epidermidis and demonstrated highest AU/ml was selected for 
molecular characterisation. The 16S ribosomal DNA was amplified by 
16S universal primers and its DNA was sequenced for strain 
identification. The strain (GAS 101) was identified as B. subtilis strain 
and 16S rDNA partial sequence was submitted to GenBank (accession 
no. KJ564301). The phylogenetic tree of amplified sequence of 16 S 
rDNA was constructed and it showed high similarity with earlier 
submitted sequences of Bacillus subspecies (fig. 1). 
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Table 2: Brief summary of antimicrobial activity of cell free supernatant of isolates against various indicator organisms by the microtiter 
plate based antimicrobial assay and antibiofilm activity against S. epidermidis by crystal violet assay. Each value represents mean of three 
























% inhibition of S. 
epidermidis 
biofilm formation  






1 GAS101 99.06±0.3 99±0.6 99.01±0.2 99.05±0.1 99.3±0.1 96.99±0.3 800 
2 GAS 201 98±0.6 94±0.3 13.7±0.1 98.1±0.3 95.13±0.4 97.04±0.5 80 
3 GAS 203 97.55±0.6 92.45±0.7 15.39±0.3 97.55±0.5 89.58±0.4 20.13±0.7 80 
4 GAS 204 93.39±0.5 91.21±0.5 11.01±0.1 98.39±0.6 17.59±0.5 20.12±0.6 160 
5 GAS 205 90.99±0.1 86.91±0.7 10.03±0.5 94.99±0.3 16.02±0.7 4.03±0.4 80 
6 GAS 206 94.63±0.2 91.28±0.2 13.56±0.4 96.63±0.2 1.04±0.3 4.86±0.6 80 
7 GAS 207 96.43±0.5 91.73±0.3 21.1±0.6 97.43±0.5 8.7±0.5 21.04±0.3 80 
8 GAS 209 97.61±0.1 90.68±0.3 11.23±0.4 98.61±0.2 12.57±0.1 28.47±0.2 160 
9 GAS 210 96.87±0.8 91.67±0.1 10.02±0.3 97.87±0.9 97.36±0.3 21.52±0.4 320 
10 GAS 211 98.65±0.4 92.65±0.8 3.65±0.7 98.65±0.7 93.23±0.5 12.5±0.7 80 
11 GAS 212 94.67±0.1 95.87±0.8 94.67±0.7 96.67±0.6 1.04±0.6 7.02±0.5 160 
12 GAS 301 92.88±0.3 84.88±0.6 84.77±0.8 94.88±0.3 82.12±0.4 70.07±0.5 640 
13 GAS 302 95.59±0.3 94.59±0.3 97.39±0.7 96.59±0.8 94.67±0.6 26.19±0.7 640 
14 GAS 402 91.55±0.8 91.55±0.5 94.65±0.4 94.55±0.1 10.87±0.4 9.05±0.5 80 
15 GAS 403 93.33±0.6 92.33±0.2 93.33±0.3 95.33±0.5 85.87±0.3 17.86±0.4 80 
16 GAS 409 94.57±0.3 95.33±0.3 94.41±0.4 96.57±0.6 10.85±0.5 9.04±0.6 80 
17 GAS 413 95.95±0.2 93.47±0.6 96.48±0.5 97.95±0.3 14.52±0.3 9.01±0.1 80 
18 GAS 503 96.79±0.6 95.39±0.5 97.41±0.1 11.37±0.1 17.42±0.4 13.7±0.5 80 
19 GAS504 96.89±0.4 94.65±0.1 97.39±0.6 16.44±0.6 3.21±0.3 13.5±0.1 160 
20 GAS505 93.58±0.3 94.78±0.3 96.53±0.7 96.58±0.8 93.27±0.2 23.05±0.7 160 
21 GAS601 94.59±0.1 95.43±0.1 95.51±0.4 96.59±0.5 93.21±0.3 23.01±0.5 160 
22 GAS 602 94.89±0.1 94.89±0.3 95.81±0.3 12.36±0.4 2.01±0.1 6.43±0.4 80 
23 GAS 603 91.55±0.3 92.55±0.7 94.75±0.1 14.37±0.1 92.72±0.4 15.91±0.6 80 
24 GAS604 90.67±0.5 91.89±0.1 95.57±0.2 11.33±0.7 1.17±0.3 7.79±0.7 160 
25 GAS605 90.79±0.4 91.88±0.2 95.19±0.5 15.21±0.2 99.02±0.5 12.74±0.9 160 
26 GAS606 97.65±0.2 95.15±0.8 96.45±0.6 12.24±0.5 96.04±0.2 19.06±0.2 80 
27 GAS607 94.65±0.1 95.65±0.7 95.05±0.5 11.27±0.7 4.03±0.1 90.05±0.6 160 
28 GAS608 92.63±0.3 93.63±0.6 96.33±0.7 14.52±0.3 20.97±0.4 8.03±0.5 80 
29 GAS609 95.46±0.5 95.46±0.6 96.66±0.8 12.35±0.2 20.77±0.3 15.73±0.1 160 
30 GAS 701 97.54±0.6 95.54±0.2 95.5±0.1 13.36±0.7 2.64±0.5 99.02±0.4 80 
 
 
Fig. 1: Phylogenetic tree of partial sequence of 16S rDNA 
amplified from isolated B. subtilis GAS101 (KJ564301) 
constructed by Clustal W showing similarity with closely 
related Bacillus subspecies 
 
DISCUSSION 
Soil typically contains 109 to 1010
S. epidermidis has the ability to colonize on the hospital device and 
form biofilm. Biofilm is multicellular, surface-attached film which 
provides architecture to microorganisms that contribute to 
resistance to antibiotics [16]. In the current study, two strains 
namely GAS 101 and GAS 301 demonstrated broad range 
antibacterial activity and in addition were able to inhibit S. 
epidermidis biofilm formation and showed disruption of biofilm. The 
molecular identification of strain GAS 101, with broader range of 
antimicrobial activity and highest (800) AU/ml against S. epidermidis 
showed this strain to be B. subtilis. CFS from isolated B. subtilis in the 
current study showed 800AU/ml against S. epidermidis whereas 
Cerein 8A, isolated from Bacillus species, was reported to have 400 
AU/ml against Listeria monocytogenes [24]. BLIS extracted from B. 
subtilis BS 15 against B. cereus showed 100 AU/ml [25].  
 microorganisms per gram (dry 
weight) which may represent more than a million bacterial species 
[17]. Soil from animal farm remains rich in straw, dung, urine and 
traces of raw milk, all of these provide an absolute atmosphere to 
cultivate. Serially diluted soil sample was allowed to grow on the 
MRS agar plate. MRS agar is a selective medium containing sodium 
acetate which suppresses the growth of other competing bacterial 
group and favours the growth of lactic acid bacteria group and 
Bacillus species [18]. In preliminary selection, S. epidermidis was 
used as an indicator organism which is an opportunistic pathogen 
reported for causing infection. In the current study 30 isolates out of 
231 showed >90 % inhibition against S. epidermidis and were 
further screened for broad range antibacterial activity. Other 
indicator organisms used in the current study belong to gram 
positive (M. luteus) and gram negative (E. coli and P. fluorescence) 
clan and have been reported to cause nosocomial infection [16, 19-
21]. These infections persist and are resilient to antibiotic treatment. 
Ten strains showed>90% inhibition against indicator organisms in the 
current study which indicates towards the broader range of growth 
restriction. Nisin, Type A (I) lantibiotic, is FDA approved and has GRAS 
status which can restrict the growth of both gram positive and gram 
negative disease causing bacteria. Though nisin is approved as food 
biopreservative, it has proved its potential for other biomedical 
applications as well [22]. Apart from LAB, antimicrobial substance 
from B. subtilis has also been reported against the broader range of 
bacteria inclusive of Salmonella, Bacillus cereus and Staphylococcus 
aureus [23]. B. subtilis can produce wide array of antimicrobial 
substances having varied biochemical and biological properties.  
The chance of developing resistance to bacteriocins due to their 
diverse mechanism of action is less as compared to antibiotics [26]. 
Despite the huge potential, there are few reports available where 
Gabrani et al. 
Int J Pharm Pharm Sci, Vol 8, Issue 10, 111-114 
 
114 
antimicrobial substances obtained from B. subtilis have been 
targeted against biofilm. Members of Bacillus group are considered 
good producers of diverse antimicrobial substances, including 
peptide, lipopeptide antibiotics and bacteriocins [6]. Bacteriocin 
from Bacillus species are of interest because of their broader range 
of activity including Gram negative bacteria and fungi [27]. 
Bacteriocin like inhibitory substance from Bacillus species has been 
reported for its antimicrobial activity and antibiofilm potential [28]. 
Sonorensin, a bacteriocin isolated from marine isolate Bacillus 
sonorensis, has exhibited S. aureus biofilm inhibition and since it 
could target both multiplying and non-multiplying bacteria, the 
resistance could not be developed against it [29].
1. Inweregbu K, Dave J, Pittard A. Nosocomial infections. Contin 
Educ Anaesth Crit Care Pain
 Lipopeptides 
isolated from B. subtilis have shown the reduction in biofilm 
formation by 88% and dispersion of mature biofilm by 81% [30]. 
CONCLUSION 
Aim of the current study was to isolate the strain with antimicrobial 
and antibiofilm potential against causative agents of nosocomial 
infection. Soil samples were collected from animal farm of twelve 
different regions. Total 231 isolates were preliminary screened against 
S. epidermidis and 30 isolates exhibiting more than 90% antimicrobial 
activity were selected. Selected strains were checked for their broader 
range of activity and the antibiofilm potential against S. epidermidis 
biofilm. Only one potential strain out of 30 showed>99 % inhibition 
against all indicator organism with highest activity unit (800AU/ml) 
against S. epidermidis. Molecular characterization by 16S rDNA 
sequencing of this strain showed it to be B. subtilis. In summary, 
antimicrobial substance isolated from the Bacillus species is a potential 
candidate as an antimicrobial and antibiofilm agent.  
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